Skip to content
Open access

Microbial modulation of CFTR modulator exposure: In vitro interactions between elexacaftor-tezacaftor-ivacaftor and pulmonary and gut bacteria from people with cystic fibrosis.

Sep 2026 · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · Vol 203, pp. 119892 · 0 citations · 44 references
Medicine

TL;DR

Elexacaftor and ivacaftor exert compound-, species- and strain-dependent effects on bacterial growth independent of their canonical role in restoring CFTR function, while multiple bacterial species decrease detectable parent-drug concentrations in culture supernatants.

Abstract

Background

Elexacaftor-tezacaftor-ivacaftor (ETI) has transformed cystic fibrosis (CF) care, but individual responses remain variable. Although longitudinal studies indicate that ETI reshapes lung and gut microbiota, the contribution of direct drug-microbe interactions remains unclear. We used an in vitro pharmacomicrobiomics approach to screen bidirectional interactions between individual cystic fibrosis transmembrane conductance regulator (CFTR) modulators and CF-relevant bacteria from pulmonary and intestinal niches.

Methods

Thirty-five Gram-positive and Gram-negative strains (15 reference strains, 20 pulmonary clinical isolates) were selected according to their frequency in CF lung and gut microbiota. Bacteria were grown in brain-heart infusion or M9 medium with or without elexacaftor, tezacaftor or ivacaftor. Growth was assessed by OD600 and CFU counts, and residual parent-drug concentrations were quantified by validated liquid chromatography-tandem mass spectrometry. Logistic growth models were fitted to OD600 data.

Results

Elexacaftor modestly increased growth of Pseudomonas aeruginosa and Escherichia coli reference strains, but not clinical P. aeruginosa isolates, suggesting strain-dependent effects. Ivacaftor inhibited all Staphylococcus aureus strains, including methicillin-resistant S. aureus, and several anaerobic commensals, while leaving P. aeruginosa and E. coli largely unaffected. Tezacaftor had no detectable effect on growth. In sterile media, all three modulators remained relatively stable. In bacteria-exposed cultures, parent-drug concentrations decreased by approximately 60-70%, with several pathogens and commensals showing high-depleting phenotypes.

Conclusions

CFTR modulators and CF-associated microbiota interact bidirectionally in vitro. Elexacaftor and ivacaftor exert compound-, species- and strain-dependent effects on bacterial growth independent of their canonical role in restoring CFTR function, while multiple bacterial species decrease detectable parent-drug concentrations in culture supernatants.

Read PDF

Similar papers

Open access Sep 2026

Ecological Patterns of Gut Microbiota During Elexacaftor/Tezacaftor/Ivacaftor Therapy in Cystic Fibrosis

Cystic fibrosis (CF) is a genetic disorder caused by CFTR gene mutations. The elexacaftor/tezacaftor/ivacaftor (ETI) drug combination has markedly improved CF outcomes; however, its impact on gut microbiota (GM) dysbiosis remains poorly investigated. Herein, we examined potential longitudinal effects of ETI treatment o...

L. Putignani, F. Ciciriello, Luigi Turco et al. · 0 citations
Open access Sep 2026

Functional and Compositional Shifts in Lung and Gut Microbiota after One Year of Treatment with Highly Effective CFTR Modulators in Cystic Fibrosis.

BACKGROUND Highly effective CFTR modulator therapy with elexacaftor-tezacaftor-ivacaftor (ETI) has revolutionized clinical outcomes in cystic fibrosis (CF), yet its effects on gut and lung microbiota, especially at the functional level, are poorly understood. METHODS In a 12-month prospective study, we enrolled 35 cl...

N. Bastón-Paz, C. García-Durán, Doĝukan Bayraktar et al. · 0 citations
Open access Sep 2026

Inhaler Devices as Potential Bacterial Reservoirs: A 30-Day Microbiota Analysis in Non-Cystic Fibrosis Bronchiectasis

Background/Objectives: Handheld inhalers are essential for the management of bronchiectasis, yet their role as potential microbial reservoirs remains poorly understood. We aimed to characterize and compare the bacterial communities in pressurized metered-dose inhalers (pMDIs) and Respimat® devices after 30 days of clin...

Jiyeon Baek, O. Sul, H. Choi et al. · 0 citations
Open access Oct 2026

CFTR Functional Rescue and Heterogeneous Clinical Outcomes Following Elexacaftor/Tezacaftor/Ivacaftor Therapy in People with Cystic Fibrosis Carrying the W1282R Variant

The clinical response to elexacaftor/tezacaftor/ivacaftor (ETI) in people with cystic fibrosis carrying the rare cystic fibrosis transmembrane conductance regulator (CFTR) variant W1282R has not been well characterized. We retrospectively analyzed 12 people with cystic fibrosis treated with ETI for 3–36 months in addit...

E. Kondratyeva, A. Efremova, Y. Melyanovskaya et al. · 0 citations
Open access Aug 2026

Anti-inflammatory and phosphorylation effects of CFTR modulator triple therapy in cystic fibrosis

Summary CFTR modulators like elexacaftor-tezacaftor-ivacaftor (ETI) improve morbidity in cystic fibrosis (CF), but their systemic effects on young children are not yet clear. We hypothesize that ETI has anti-inflammatory effects and reverse disease-associated molecular signatures in children with CF. This exploratory p...

H. Selvadurai, V. Han, Brooke A. Keating et al. · 0 citations
Open access Oct 2026

Sex-Dependent Microbiome-Metabolome Remodeling Associated with Bacteroides acidifaciens Modulation of Acute Respiratory Distress Syndrome

Acute respiratory distress syndrome (ARDS) is a severe lung disorder influenced by the interplay between the intestinal microbiome, host metabolism, and immune function. We previously found that Bacteroides acidifaciens (BA) has opposing effects on staphylococcal enterotoxin B (SEB)-induced ARDS, worsening the conditio...

S. Staley, Carly Cooper, Stacey Oxendine et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.